Dexmedetomidine Accord



This medicine is authorised for use in the European Union.


Dexmedetomidine Accord is a medicine used to sedate (calm or make sleepy) adults in the following settings:

  • in hospital intensive care units to bring about a light level of sedation in which the patient can still respond to verbal stimulation (corresponding to a score of between 0 and -3 on the Richmond Agitation-Sedation Scale);
  • before or during diagnostic or surgical procedures where the patient remains awake (awake sedation).

Dexmedetomidine Accord contains the active substance dexmedetomidine.

Dexmedetomidine Accord is a ‘generic medicine’. This means that Dexmedetomidine Accord contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU called Dexdor.

This EPAR was last updated on 25/01/2023

Authorisation details

Product details
Dexmedetomidine Accord
Agency product number
Active substance
International non-proprietary name (INN) or common name
Therapeutic area (MeSH)
Anatomical therapeutic chemical (ATC) code

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.

Publication details
Marketing-authorisation holder
Accord Healthcare S.L.U.
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Accord Healthcare S.L.U.
Edificio Este Planta 6a
World Trade Center
Moll De Barcelona S/n
08039 Barcelona

Product information

24/01/2023 Dexmedetomidine Accord - EMEA/H/C/005152 - IB/0011

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group


Therapeutic indication

For sedation of adult ICU (Intensive Care Unit) patients requiring a sedation level not deeper than arousal in response to verbal stimulation (corresponding to Richmond Agitation-Sedation Scale (RASS) 0 to -3).

For sedation of non-intubated adult patients prior to and/or during diagnostic or surgical procedures requiring sedation, i.e. procedural/awake sedation.

Assessment history

How useful was this page?

Add your rating
1 rating